Arie Bellde­grun's Vi­da Ven­tures goes back to the well with $825M mega­fund and its eyes set on more in­no­v­a­tive meds

Among the list of bright names in bio­phar­ma, few shine brighter than Kite founder and se­r­i­al en­tre­pre­neur Arie Bellde­grun, who has rat­tled off a re­mark­able run of suc­cess in re­cent years. Now, a Bellde­grun in­vest­ment team is lock­ing up a mas­sive third fund to keep chas­ing the cut­ting edge in ther­a­peu­tics.

Vi­da Ven­tures closed its third in­vest­ment fund at a whop­ping $825 mil­lion — its largest yet — as the ever-ex­pand­ing VC firm hits 30 com­pa­nies in its port­fo­lio de­vel­op­ing new routes to hard-to-treat dis­eases, the com­pa­ny said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER